

# Gennaro Ciliberto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8546619/publications.pdf>

Version: 2024-02-01

467  
papers

28,808  
citations

6486

82  
h-index

9118

149  
g-index

493  
all docs

493  
docs citations

493  
times ranked

33395  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2. <i>British Journal of Haematology</i> , 2022, 196, 362-367.	1.2	15
2	COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models. <i>Molecular Therapy</i> , 2022, 30, 311-326.	3.7	54
3	Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. <i>Leukemia</i> , 2022, 36, 588-590.	3.3	23
4	An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 646.	1.7	5
5	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 733-744.	1.9	6
6	Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. <i>Npj Vaccines</i> , 2022, 7, 15.	2.9	17
7	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
8	mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients. <i>Frontiers in Oncology</i> , 2022, 12, 855723.	1.3	8
9	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously". <i>Journal of Thoracic Oncology</i> , 2022, 17, e40-e41.	0.5	1
10	KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. <i>Journal of Thoracic Oncology</i> , 2022, 17, 751-757.	0.5	21
11	COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors. <i>Neurological Sciences</i> , 2022, 43, 3519-3522.	0.9	4
12	TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer. <i>Cancer Letters</i> , 2022, 533, 215607.	3.2	9
13	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
14	Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. , 2022, 10, e004239.		6
15	Optimizing the Illumina COVIDSeq laboratorial and bioinformatics pipeline on thousands of samples for SARS-CoV-2 Variants of Concern tracking. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2558-2563.	1.9	2
16	A Real-World Systematic Analysis of Driver Mutations™ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting. <i>Cancers</i> , 2022, 14, 2971.	1.7	6
17	Volatilome Analysis in Prostate Cancer by Electronic Nose: A Pilot Monocentric Study. <i>Cancers</i> , 2022, 14, 2927.	1.7	14
18	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists. <i>International Journal of Medical Sciences</i> , 2021, 18, 2235-2238.	1.1	2
20	Istituti Fisioterapici Ospitalieri (IFO) ed emergenza sanitaria da Coronavirus: l'esperienza maturata durante la fase di lockdown e la fase 2 Covid-19. <i>Mecosan</i> , 2021, , 49-77.	0.0	0
21	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	1.1	5
22	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	1.7	13
23	The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 645069.	1.3	18
24	COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. <i>Breast Journal</i> , 2021, 27, 359-362.	0.4	5
25	Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101013.	1.7	10
26	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3837.	1.8	22
27	Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. <i>Journal of Translational Medicine</i> , 2021, 19, 139.	1.8	13
28	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	1.0	16
29	Emerging therapeutics. <i>Journal of Translational Medicine</i> , 2021, 19, 195.	1.8	0
30	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. <i>Journal of Hematology and Oncology</i> , 2021, 14, 81.	6.9	149
31	Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. <i>Vaccines</i> , 2021, 9, 685.	2.1	43
32	H-Ras gene takes part to the host immune response to COVID-19. <i>Cell Death Discovery</i> , 2021, 7, 158.	2.0	11
33	Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. <i>EClinicalMedicine</i> , 2021, 36, 100928.	3.2	135
34	Italy: scientists petition against biodynamic farming law. <i>Nature</i> , 2021, 595, 352-352.	18.7	3
35	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e637-e641.	1.1	4
36	MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study. <i>Biomarker Research</i> , 2021, 9, 57.	2.8	10

#	ARTICLE	IF	CITATIONS
37	Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 119.	6.9	35
38	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
39	Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 690322.	2.2	0
40	SCD1, autophagy and cancer: implications for therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 265.	3.5	57
41	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077.	0.5	28
42	Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. <i>Cancers</i> , 2021, 13, 4061.	1.7	5
43	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. <i>Frontiers in Immunology</i> , 2021, 12, 704110.	2.2	22
44	Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 79-85.	0.6	1
45	Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. <i>Oncolimmunology</i> , 2021, 10, 1898832.	2.1	15
46	Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. <i>Vaccines</i> , 2021, 9, 1125.	2.1	37
47	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	2.7	3
48	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
49	CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions. <i>Journal of Cellular Physiology</i> , 2020, 235, 1877-1887.	2.0	29
50	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
51	T-cell agonists in cancer immunotherapy. , 2020, 8, e000966.		69
52	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. <i>Annals of Oncology</i> , 2020, 31, 1746-1754.	0.6	140
53	Drug tolerance to target therapy in melanoma revealed at single cell level: What next?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188440.	3.3	12
54	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213.	3.5	26

#	ARTICLE	IF	CITATIONS
55	Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. <i>Frontiers in Oncology</i> , 2020, 10, 922.	1.3	1
56	Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma. <i>Cancers</i> , 2020, 12, 3368.	1.7	15
57	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
58	Pyruvium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Cell-Like Cells and Reduces Metastases through Effects on Lipid Anabolism. <i>Cancer Research</i> , 2020, 80, 4087-4102.	0.4	36
59	Reorganization of Istituti Fisioterapici Ospitalieri, an oncological and dermatological clinical and research center, to face the coronavirus health emergency: adopted measures and metrics of success to achieve and keep a COVID-19-free status. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 177.	3.5	1
60	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 200.	3.5	25
61	Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 171.	3.5	12
62	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. <i>Cell Communication and Signaling</i> , 2020, 18, 150.	2.7	4
63	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	1.7	17
64	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	0.8	130
65	Cancer patients and coronavirus disease 2019: evidence in context. <i>Journal of Translational Medicine</i> , 2020, 18, 315.	1.8	6
66	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
67	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
68	The Experience of Oncology Healthcare Providers in the Central Italy during the COVID-19 Lockdown. <i>Cancers</i> , 2020, 12, 3031.	1.7	5
69	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	1.8	30
70	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
71	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
72	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 111.	3.5	14

#	ARTICLE	IF	CITATIONS
73	The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape. <i>Cell Death and Disease</i> , 2020, 11, 471.	2.7	25
74	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1930.	1.8	15
75	A moonshot approach toward the management of cancer patients in the COVID-19 time: what have we learned and what could the Italian network of cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 109.	3.5	9
76	Are Genetic Vaccines the Right Weapon against COVID-19?. <i>Molecular Therapy</i> , 2020, 28, 1555-1556.	3.7	16
77	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. <i>International Journal of Biological Markers</i> , 2020, 35, 8-11.	0.7	15
78	microRNA-378a-5p is a novel positive regulator of melanoma progression. <i>Oncogenesis</i> , 2020, 9, 22.	2.1	30
79	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
80	Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study. <i>Journal of Translational Medicine</i> , 2020, 18, 39.	1.8	18
81	Boosting the arsenal against COVID-19 through computational drug repurposing. <i>Drug Discovery Today</i> , 2020, 25, 946-948.	3.2	43
82	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. <i>Cancers</i> , 2020, 12, 849.	1.7	2
83	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. <i>Journal of Translational Medicine</i> , 2020, 18, 494.	1.8	15
84	Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e199.	1.7	1
85	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2019, 79, 5612-5625.	0.4	11
86	Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. <i>Cell Death and Disease</i> , 2019, 10, 827.	2.7	35
87	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
88	Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 459.	3.5	9
89	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1924-1934.	0.5	60
90	B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1928.	1.0	13

#	ARTICLE	IF	CITATIONS
91	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	2
92	Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity. <i>Scientific Reports</i> , 2019, 9, 12169.	1.6	11
93	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers</i> , 2019, 11, 1425.	1.7	22
94	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
95	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. <i>Journal of Translational Medicine</i> , 2019, 17, 131.	1.8	17
96	Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 78.	3.5	32
97	Look for methods, not conclusions. <i>Cell Death and Disease</i> , 2019, 10, 931.	2.7	1
98	P1.01-59 Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy. <i>Journal of Thoracic Oncology</i> , 2019, 14, S381.	0.5	0
99	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	1.2	16
100	Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer. <i>Medicine (United States)</i> , 2019, 98, e17135.	0.4	1
101	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	1.5	30
102	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 53-68.	1.5	6
103	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
104	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death and Differentiation</i> , 2019, 26, 1267-1282.	5.0	47
105	The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11
106	Metabolic features of cancer stem cells: the emerging role of lipid metabolism. <i>Oncogene</i> , 2018, 37, 2367-2378.	2.6	101
107	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	1.5	12
108	HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. <i>Oncogene</i> , 2018, 37, 1369-1385.	2.6	19



#	ARTICLE	IF	CITATIONS
109	The perfect personalized cancer therapy: cancer vaccines against neoantigens. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 86.	3.5	82
110	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	2.0	33
111	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 318.	3.5	66
112	Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. <i>Journal of Translational Medicine</i> , 2018, 16, 349.	1.8	19
113	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
114	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1465163.	2.1	6
115	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	1.8	16
116	Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers. <i>Scientific Reports</i> , 2018, 8, 10395.	1.6	7
117	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
118	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13
119	Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 95.	3.5	25
120	Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 47.	3.5	60
121	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	6.3	1,487
122	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. <i>Oncotarget</i> , 2018, 9, 3576-3589.	0.8	19
123	Epigenetic Changes Induced by Green Tea Catechins are Associated with Prostate Cancer. <i>Current Molecular Medicine</i> , 2018, 17, 405-420.	0.6	26
124	Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. <i>BMC Cancer</i> , 2017, 17, 69.	1.1	31
125	Combining doxorubicin with a phenolic extract from flaxseed oil: Evaluation of the effect on two breast cancer cell lines. <i>International Journal of Oncology</i> , 2017, 50, 468-476.	1.4	13
126	Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. <i>Scientific Reports</i> , 2017, 7, 1312.	1.6	19



#	ARTICLE	IF	CITATIONS
127	MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 39-48.	3.2	26
128	Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. <i>Oncogene</i> , 2017, 36, 4573-4584.	2.6	123
129	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>OncoImmunology</i> , 2017, 6, e1261242.	2.1	59
130	Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017, 38, 2741-2751.	1.2	22
131	An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer. <i>Molecular BioSystems</i> , 2017, 13, 2687-2696.	2.9	0
132	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	1.6	14
133	Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells. <i>Cancer Letters</i> , 2017, 406, 93-104.	3.2	93
134	Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes. <i>Journal of Cellular Physiology</i> , 2017, 232, 1144-1150.	2.0	13
135	Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. <i>Oncotarget</i> , 2017, 8, 30606-30616.	0.8	40
136	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 223.	1.8	25
137	Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 128.	3.5	18
138	Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 180.	3.5	17
139	MicroRNAs in melanoma development and resistance to target therapy. <i>Oncotarget</i> , 2017, 8, 22262-22278.	0.8	89
140	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	1.1	5
141	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	0.8	53
142	Environment and bladder cancer: molecular analysis by interaction networks. <i>Oncotarget</i> , 2017, 8, 65240-65252.	0.8	39
143	Efficacy and safety of 5% lidocaine-mediated plasters in localized pain with neuropathic and/or inflammatory characteristics: an observational, real-world study. <i>European Review for Medical and Pharmacological Sciences</i> , 2017, 21, 4228-4235.	0.5	3
144	Serum Cytokine Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11.	1.4	26

#	ARTICLE	IF	CITATIONS
145	Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric Carcinogenesis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-11.	1.9	26
146	Differential Response of Two Human Breast Cancer Cell Lines to the Phenolic Extract from Flaxseed Oil. <i>Molecules</i> , 2016, 21, 319.	1.7	16
147	Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". <i>Frontiers in Pharmacology</i> , 2016, 7, 287.	1.6	10
148	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 331.	1.6	13
149	Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles. <i>Molecules</i> , 2016, 21, 1411.	1.7	57
150	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. <i>Oncotarget</i> , 2016, 7, 18865-18875.	0.8	26
151	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	3.4	102
152	Genetic and Functional Analysis of Polymorphisms in the Human Dopamine Receptor and Transporter Genes in Small Cell Lung Cancer. <i>Journal of Cellular Physiology</i> , 2016, 231, 345-356.	2.0	18
153	miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5005-13.	3.3	99
154	A study on the structural features of SELK, an over-expressed protein in hepatocellular carcinoma, by molecular dynamics simulations in a lipid-water system. <i>Molecular BioSystems</i> , 2016, 12, 3209-3222.	2.9	12
155	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. <i>Scientific Reports</i> , 2016, 6, 29258.	1.6	22
156	Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. <i>Journal of Translational Medicine</i> , 2016, 14, 61.	1.8	43
157	Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women. <i>Current Research in Translational Medicine</i> , 2016, 64, 15-20.	1.2	8
158	Combinatorial immunotherapy strategies for hepatocellular carcinoma. <i>Current Opinion in Immunology</i> , 2016, 39, 103-113.	2.4	52
159	Deducing the functional characteristics of the human selenoprotein SELK from the structural properties of its intrinsically disordered C-terminal domain. <i>Molecular BioSystems</i> , 2016, 12, 758-772.	2.9	11
160	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. <i>Journal of Translational Medicine</i> , 2016, 14, 58.	1.8	18
161	Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. <i>Oncogene</i> , 2016, 35, 1143-1152.	2.6	12
162	The Elapsed Time During a Virtual Reality Treatment for Stressful Procedures. A Pool Analysis on Breast Cancer Patients During Chemotherapy. <i>Smart Innovation, Systems and Technologies</i> , 2016, , 731-738.	0.5	7

#	ARTICLE	IF	CITATIONS
163	Abstract 1070: miR-579-3p is a novel master regulator of melanoma progression and drug resistance in metastatic melanoma. , 2016, , .		2
164	Human MiR-544a Modulates SELK Expression in Hepatocarcinoma Cell Lines. PLoS ONE, 2016, 11, e0156908.	1.1	18
165	Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. Oncotarget, 2016, 7, 62019-62033.	0.8	62
166	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget, 2016, 7, 85641-85649.	0.8	22
167	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget, 2016, 7, 19559-19574.	0.8	20
168	Abstract A043: Safety and efficacy of a genetic vaccine targeting telomerase against various canine cancers. , 2016, , .		0
169	Abstract B130: Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy. , 2016, , .		0
170	Abstract 1052: Stearoyl-CoA-Desaturase (SCD1) regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. , 2016, , .		0
171	Abstract 742: A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice. , 2016, , .		0
172	Strain Analysis in the Assessment of a Mouse Model of Cardiotoxicity due to Chemotherapy: Sample for Preclinical Research. In Vivo, 2016, 30, 279-90.	0.6	18
173	Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy. Anticancer Research, 2016, 36, 2119-24.	0.5	4
174	Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer, 2015, 15, 720.	1.1	42
175	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. Journal of Translational Medicine, 2015, 13, 360.	1.8	10
176	The Organization of Clinical Trials for Oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the Impact of the OEI Accreditation Process. Tumori, 2015, 101, S33-S37.	0.6	0
177	Anti-Inflammatory Effects of a Methanol Extract from the Marine Sponge <i>Geodia cydonium</i> on the Human Breast Cancer MCF-7 Cell Line. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	25
178	Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	44
179	Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget, 2015, 6, 26560-26574.	0.8	133
180	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 1305-1314.	2.0	31

#	ARTICLE	IF	CITATIONS
181	BMI and breast cancer prognosis benefit: Mammography screening reveals differences between normal weight and overweight women. <i>Breast</i> , 2015, 24, 86-89.	0.9	10
182	Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC. <i>European Radiology</i> , 2015, 25, 1935-1945.	2.3	44
183	P127 Metabolic syndrome and breast cancer risk by molecular subtype. <i>Breast</i> , 2015, 24, S68.	0.9	0
184	ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	2
185	Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen. <i>Human Gene Therapy</i> , 2015, 26, 386-398.	1.4	7
186	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008842.	2.1	72
187	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 89, 287-299.	1.3	73
188	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. <i>Oncotarget</i> , 2015, 6, 24823-24841.	0.8	29
189	The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells. <i>Oncotarget</i> , 2015, 6, 42667-42686.	0.8	43
190	Abstract 4230: Targeting lung cancer stem cells through fatty acid metabolism. , 2015, , .		0
191	Abstract 291: Targeting the stroma to hit the tumor: MMP11 as a novel target for cancer immunotherapy. , 2015, , .		0
192	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	2.1	318
193	Lung Cancer Stem Cell Lose Their Stemness Default State after Exposure to Microgravity. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	48
194	Immunogenicity and Therapeutic Efficacy of a Dual-Component Genetic Cancer Vaccine Cotargeting Carcinoembryonic Antigen and HER2/neu in Preclinical Models. <i>Human Gene Therapy</i> , 2014, 25, 121-131.	1.4	23
195	Breast cancer screening, body mass index and prognosis benefit. <i>Journal of Medical Screening</i> , 2014, 21, 165-166.	1.1	0
196	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 105.	1.2	17
197	Xenogene vaccination in the therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1427-1442.	1.4	16
198	A novel minigene scaffold for therapeutic cancer vaccines. <i>Oncolmmunology</i> , 2014, 3, e27529.	2.1	15

#	ARTICLE	IF	CITATIONS
199	Electro-gene transfer as a new tool for cancer immunotherapy in animals. <i>Veterinary and Comparative Oncology</i> , 2014, 12, 310-318.	0.8	24
200	Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5184-5194.	0.4	251
201	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 216.	1.8	43
202	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	2.0	230
203	Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. <i>Journal of Translational Medicine</i> , 2014, 12, 54.	1.8	36
204	Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition. <i>Journal of Translational Medicine</i> , 2014, 12, O2.	1.8	0
205	MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPilimumab. <i>Journal of Translational Medicine</i> , 2014, 12, P11.	1.8	12
206	Immunoscore: a new possible approach for melanoma classification. , 2014, 2, .		9
207	Mortality trend for liver cancer in a hyperendemic area of hepatitis C virus infection in southern Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 245-246.	0.8	2
208	Phase III study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9105-TPS9105.	0.8	0
209	Abstract 5444: Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients. , 2014, , .		0
210	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. <i>Journal of Translational Medicine</i> , 2013, 11, 180.	1.8	61
211	Phase I studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. <i>Journal of Translational Medicine</i> , 2013, 11, 62.	1.8	70
212	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 54.	1.8	104
213	Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 14.	3.5	29
214	Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell Lymphoma. <i>Human Gene Therapy</i> , 2013, 24, 728-738.	1.4	47
215	Decreased expression of autophagic beclin 1 protein in idiopathic pulmonary fibrosis fibroblasts. <i>Journal of Cellular Physiology</i> , 2013, 228, 1516-1524.	2.0	64
216	New developments in cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1109-1110.	2.0	5

#	ARTICLE	IF	CITATIONS
217	Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. <i>Trials</i> , 2013, 14, 273.	0.7	25
218	EMT markers in lung adenocarcinoma pleural effusion spheroid cells. <i>Journal of Cellular Physiology</i> , 2013, 228, 1720-1726.	2.0	28
219	Interleukin 18: Friend or foe in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 296-303.	3.3	47
220	TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung. <i>Cell Cycle</i> , 2013, 12, 1696-1703.	1.3	30
221	Cancer vaccination by electro-gene-transfer. <i>Expert Review of Vaccines</i> , 2013, 12, 1127-1137.	2.0	28
222	Kinesin spindle protein SiRNA slows tumor progression. <i>Journal of Cellular Physiology</i> , 2013, 228, 58-64.	2.0	25
223	Homeodomain-interacting protein kinase2 in human idiopathic pulmonary fibrosis. <i>Journal of Cellular Physiology</i> , 2013, 228, 235-241.	2.0	26
224	Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy. <i>Cancer Biology and Therapy</i> , 2013, 14, 1113-1122.	1.5	13
225	Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 1665-1673.	1.2	16
226	Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. <i>Cell Death and Disease</i> , 2013, 4, e947-e947.	2.7	121
227	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer. <i>Oncotarget</i> , 2013, 4, 1253-1265.	0.8	38
228	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. <i>Tumori</i> , 2013, 99, 293e-8e.	0.6	3
229	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. <i>Cell Cycle</i> , 2012, 11, 1455-1467.	1.3	29
230	On the connections between cancer stem cells and EMT. <i>Cell Cycle</i> , 2012, 11, 4301-4301.	1.3	8
231	An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. <i>Oncolmmunology</i> , 2012, 1, 1258-1270.	2.1	16
232	Intrablastocyst injection with human CD34+/CD133+ cells increase survival of immunocompetent fumarylacetoacetate hydrolase knockout mice. <i>Laboratory Animals</i> , 2012, 46, 280-286.	0.5	1
233	Tumor biobanks in translational medicine. <i>Journal of Translational Medicine</i> , 2012, 10, 204.	1.8	17
234	WT1 CpG islands methylation in human lung cancer: A pilot study. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 306-309.	1.0	11

#	ARTICLE	IF	CITATIONS
235	Genetic cancer vaccines: current status and perspectives. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1043-1058.	1.4	62
236	Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. <i>Journal of Cellular Physiology</i> , 2012, 227, 3381-3388.	2.0	29
237	The promise of anti-ErbB3 monoclonals as new cancer therapeutics. <i>Oncotarget</i> , 2012, 3, 744-758.	0.8	75
238	Abstract 2846: Exploring ERBB3 as novel drug target in lung cancer. , 2012, , .		0
239	Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration. <i>Translational Oncology</i> , 2011, 4, 38-IN2.	1.7	12
240	Spheres Derived from Lung Adenocarcinoma Pleural Effusions: Molecular Characterization and Tumor Engraftment. <i>PLoS ONE</i> , 2011, 6, e21320.	1.1	60
241	Intratumor RNA interference of cell cycle genes slows down tumor progression. <i>Gene Therapy</i> , 2011, 18, 727-733.	2.3	15
242	Emerging Cancer Vaccines: The Promise of Genetic Vectors. <i>Cancers</i> , 2011, 3, 3687-3713.	1.7	16
243	Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. <i>BMC Cancer</i> , 2010, 10, 129.	1.1	32
244	Synthesis and anti-hepatitis C virus activity of novel ethyl 1H-indole-3-carboxylates in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6143-6148.	1.4	27
245	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like and early progenitor-targeting drugs. <i>Cell Cycle</i> , 2010, 9, 2950-2959.	1.3	86
246	224 Her3 as an emerging target for lung tumor initiating cells. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 73.	2.2	0
247	A Vaccine Targeting Telomerase Enhances Survival of Dogs Affected by B-cell Lymphoma. <i>Molecular Therapy</i> , 2010, 18, 1559-1567.	3.7	66
248	Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. <i>Vaccine</i> , 2010, 28, 1201-1208.	1.7	43
249	A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. <i>Vaccine</i> , 2010, 28, 3522-3530.	1.7	18
250	Neurotrophin system activation in pleural effusions. <i>Growth Factors</i> , 2010, 28, 221-231.	0.5	9
251	Patented cancer vaccines: the promising leads. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 647-660.	2.4	10
252	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like and early progenitor-targeting drugs. <i>Cell Cycle</i> , 2010, 9, 2878-87.	1.3	51



#	ARTICLE	IF	CITATIONS
253	Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. <i>Journal of Oncology</i> , 2009, 2009, 1-10.	0.6	28
254	ErbB2 Genetic Cancer Vaccine in Nonhuman Primates: Relevance of Single Nucleotide Polymorphisms. <i>Human Gene Therapy</i> , 2009, 20, 253-265.	1.4	14
255	IL-6 Is Required for Airway Mucus Production Induced by Inhaled Fungal Allergens. <i>Journal of Immunology</i> , 2009, 183, 1732-1738.	0.4	113
256	Antiapoptotic Small Interfering RNA as Potent Adjuvant of DNA Vaccination in a Mouse Mammary Tumor Model. <i>Human Gene Therapy</i> , 2009, 20, 589-597.	1.4	19
257	MMP11: A Novel Target Antigen for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2009, 15, 4104-4113.	3.2	74
258	A Therapeutic Cancer Vaccine Targeting Carcinoembryonic Antigen in Intestinal Carcinomas. <i>Human Gene Therapy</i> , 2009, 20, 125-136.	1.4	18
259	Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates. <i>Molecular Therapy</i> , 2009, 17, 1804-1813.	3.7	22
260	Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9. <i>Clinical Cancer Research</i> , 2009, 15, 1575-1584.	3.2	44
261	The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2009, 206, 69-78.	4.2	370
262	Comparative expression pathway analysis of human and canine mammary tumors. <i>BMC Genomics</i> , 2009, 10, 135.	1.2	141
263	An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. <i>Cancer Gene Therapy</i> , 2009, 16, 462-472.	2.2	20
264	A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. <i>Vaccine</i> , 2009, 27, 1293-1300.	1.7	48
265	Synthetic Peptide Vaccines: The Quest to Develop Peptide Vaccines for Influenza, HIV and Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2009, 611, 121-123.	0.8	2
266	A Novel Mouse Model for Evaluation and Prediction of HLA-A2-restricted CEA Cancer Vaccine Responses. <i>Journal of Immunotherapy</i> , 2009, 32, 744-754.	1.2	15
267	Synergistic effect of geneâ€electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. <i>Journal of Gene Medicine</i> , 2008, 10, 1048-1054.	1.4	9
268	Therapeutic Vaccination Halts Disease Progression in BALB-neuT Mice: The Amplitude of Elicited Immune Response Is Predictive of Vaccine Efficacy. <i>Human Gene Therapy</i> , 2008, 19, 670-680.	1.4	34
269	Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer. <i>Cancer Research</i> , 2008, 68, 9865-9874.	0.4	42
270	Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. <i>Cardiovascular Research</i> , 2008, 80, 416-424.	1.8	147

#	ARTICLE	IF	CITATIONS
271	A Therapeutic Cancer Vaccine Targeting Carcinoembryonic Antigen in Intestinal Carcinomas. Human Gene Therapy, 2008, .	1.4	1
272	Her2/neu genetic cancer vaccine in non human primates: relevance of single nucleotide polymorphisms. Human Gene Therapy, 2008, .	1.4	1
273	Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine, 2007, 26, 47-58.	1.7	35
274	Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. International Journal of Cancer, 2007, 120, 2290-2300.	2.3	39
275	Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. Journal of Gene Medicine, 2007, 9, 862-874.	1.4	48
276	CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Therapy, 2007, 14, 201-210.	2.2	16
277	A Structure-Guided Approach to an Orthogonal Estrogen-Receptor-Based Gene Switch Activated by Ligands Suitable for in Vivo Studies. Journal of Medicinal Chemistry, 2006, 49, 5404-5407.	2.9	19
278	Identification of a Novel HIV-1 Neutralizing Antibody Using Synthetic Peptides that Mimic a GP41 Fusion Intermediate. , 2006, , 569-570.		0
279	CD8+ T-Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T-Cell Tolerance is Broken by Additional Co-administration of a Toll-Like Receptor Ligand. Scandinavian Journal of Immunology, 2006, 63, 35-41.	1.3	19
280	Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: Initial identification of predictive biomarkers. European Journal of Immunology, 2006, 36, 1337-1349.	1.6	12
281	DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection. Human Gene Therapy, 2006, 17, 81-92.	1.4	41
282	Modulation of the Immune Response Induced by Gene Electrotransfer of a Hepatitis C Virus DNA Vaccine in Nonhuman Primates. Journal of Immunology, 2006, 177, 7462-7471.	0.4	82
283	Genetic vaccination by gene electro-transfer in non-human primates. Journal of Drug Delivery Science and Technology, 2006, 16, 85-89.	1.4	4
284	A Functionally Orthogonal Estrogen Receptor-Based Transcription Switch Specifically Induced by a Nonsteroid Synthetic Ligand. Chemistry and Biology, 2005, 12, 883-893.	6.2	18
285	Adenovirus Transduction and Culture Conditions Affect the Immunogenicity of Murine Dendritic Cells. Scandinavian Journal of Immunology, 2005, 62, 206-217.	1.3	10
286	Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. International Journal of Cancer, 2005, 117, 444-455.	2.3	65
287	Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. Journal of Gene Medicine, 2005, 7, 228-236.	1.4	58
288	Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector. Journal of Gene Medicine, 2005, 7, 1086-1096.	1.4	26

#	ARTICLE	IF	CITATIONS
289	In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters. <i>Journal of Gene Medicine</i> , 2005, 7, 1475-1481.	1.4	28
290	Regulated and Liver-Specific Tamarin Alpha Interferon Gene Delivery by a Helper-Dependent Adenoviral Vector. <i>Journal of Virology</i> , 2005, 79, 6772-6780.	1.5	14
291	A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14759-14764.	3.3	136
292	Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor. <i>Journal of Virology</i> , 2005, 79, 7380-7388.	1.5	64
293	An Adenovirus Type 5 (Ad5) Amplicon-Based Packaging Cell Line for Production of High-Capacity Helper-Independent 1 <sup>st</sup> E1-E2-E3-E4 Ad5 Vectors. <i>Journal of Virology</i> , 2005, 79, 6400-6409.	1.5	24
294	DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection. <i>Human Gene Therapy</i> , 2005, .	1.4	0
295	Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. <i>Molecular Vision</i> , 2005, 11, 366-73.	1.1	36
296	A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent. <i>Cell Death and Differentiation</i> , 2004, 11, S2-S4.	5.0	22
297	Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. <i>Gene Therapy</i> , 2004, 11, 711-721.	2.3	272
298	Gene therapy progress and prospects: transcription regulatory systems. <i>Gene Therapy</i> , 2004, 11, 649-657.	2.3	136
299	Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. <i>Journal of Immunological Methods</i> , 2004, 287, 49-65.	0.6	33
300	Susceptibility to audiogenic seizure and neurotransmitter amino acid levels in different brain areas of IL-6-deficient mice. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 78, 75-81.	1.3	28
301	Gene electro-transfer improves transduction by modifying the fate of intramuscular DNA. <i>Journal of Gene Medicine</i> , 2003, 5, 324-332.	1.4	70
302	High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. <i>Clinical and Experimental Immunology</i> , 2003, 131, 355-363.	1.1	13
303	Structural Analysis of the Epitope of the Anti-HIV Antibody 2F5 Sheds Light into Its Mechanism of Neutralization and HIV Fusion. <i>Journal of Molecular Biology</i> , 2003, 330, 1101-1115.	2.0	125
304	Construction of an rtTA2s-m2/ttskld-Based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and Non-Human primates. <i>Molecular Therapy</i> , 2003, 7, 271-280.	3.7	78
305	Long-Term and Tight Control of Gene Expression in Mouse Skeletal Muscle by a New Hybrid Human Transcription Factor. <i>Molecular Therapy</i> , 2002, 6, 653-663.	3.7	11
306	Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 2369-2375.	0.6	12

#	ARTICLE	IF	CITATIONS
307	Hyaluronidase Increases Electroporation Efficiency in Skeletal Muscle. <i>Human Gene Therapy</i> , 2002, 13, 355-365.	1.4	61
308	Stringent Control of Gene Expression In Vivo by Using Novel Doxycycline-Dependent Trans-Activators. <i>Human Gene Therapy</i> , 2002, 13, 199-210.	1.4	85
309	Long-Term and Tight Control of Gene Expression in Mouse Skeletal Muscle by a New Hybrid Human Transcription Factor. <i>Molecular Therapy</i> , 2002, 6, 653-663.	3.7	26
310	Electro-gene-transfer: a new approach for muscle gene delivery. <i>Somatic Cell and Molecular Genetics</i> , 2002, 27, 75-83.	0.7	37
311	Synergistic Stimulation of Interleukin 6 Release and Gene Expression by Phorbol Esters and Interleukin 1 $\beta$ in Rat Cortical Astrocytes: Role of Protein Kinase C Activation and Blockade. <i>Journal of Neurochemistry</i> , 2002, 64, 1945-1953.	2.1	16
312	Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system. <i>Gene Therapy</i> , 2002, 9, 1415-1421.	2.3	71
313	Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. <i>Molecular Therapy</i> , 2002, 6, 653-63.	3.7	6
314	Global changes in interleukin-6-dependent gene expression patterns in mouse livers after partial hepatectomy. <i>Hepatology</i> , 2001, 33, 1377-1386.	3.6	99
315	Antitumor activity of recombinant adenoviral vectors expressing murine IFN- $\gamma$ in mice injected with metastatic IFN-resistant tumor cells. <i>Cancer Gene Therapy</i> , 2001, 8, 63-72.	2.2	24
316	Regulated and prolonged expression of mIFN- $\gamma$ in immunocompetent mice mediated by a helper-dependent adenovirus vector. <i>Gene Therapy</i> , 2001, 8, 1817-1825.	2.3	37
317	Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. <i>European Heart Journal</i> , 2001, 22, 964-971.	1.0	65
318	Interleukin-6-Induced STAT3 and AP-1 Amplify Hepatocyte Nuclear Factor 1-Mediated Transactivation of Hepatic Genes, an Adaptive Response to Liver Injury. <i>Molecular and Cellular Biology</i> , 2001, 21, 414-424.	1.1	121
319	In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist. <i>Journal of Immunology</i> , 2001, 166, 4334-4340.	0.4	47
320	Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL. <i>Journal of Biological Chemistry</i> , 2001, 276, 26605-26613.	1.6	265
321	Identification and Characterization of a Novel Nuclear Factor of Activated T-cells-1 Isoform Expressed in Mouse Brain. <i>Journal of Biological Chemistry</i> , 2001, 276, 14350-14358.	1.6	44
322	An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5986-5991.	3.3	93
323	Interleukin-6 Involvement in Antidepressant Action of Hypericum Perforatum. <i>Pharmacopsychiatry</i> , 2001, 34, 8-10.	1.7	34
324	Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. <i>Hepatology</i> , 2000, 31, 149-159.	3.6	285

#	ARTICLE	IF	CITATIONS
325	Leptin receptor-mediated regulation of cholinergic neurotransmitter phenotype in cells of central nervous system origin. FEBS Journal, 2000, 267, 2939-2944.	0.2	9
326	Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death and Differentiation, 2000, 7, 327-328.	5.0	31
327	Prolonged Expression and Effective Readministration of Erythropoietin Delivered with a Fully Deleted Adenoviral Vector. Human Gene Therapy, 2000, 11, 859-868.	1.4	84
328	Gene Electrotransfer Results in a High-Level Transduction of Rat Skeletal Muscle and Corrects Anemia of Renal Failure. Human Gene Therapy, 2000, 11, 1891-1900.	1.4	93
329	Selective Cleavage of AAVS1 Substrates by the Adeno-Associated Virus Type 2 Rep68 Protein Is Dependent on Topological and Sequence Constraints. Journal of Virology, 2000, 74, 8831-8842.	1.5	23
330	Conditional Site-Specific Integration into Human Chromosome 19 by Using a Ligand-Dependent Chimeric Adeno-Associated Virus/Rep Protein. Journal of Virology, 2000, 74, 281-294.	1.5	35
331	Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis. Journal of Virology, 2000, 74, 4816-4823.	1.5	53
332	CCAAT enhancer binding protein B is required for Fas-induced apoptosis in liver. Gastroenterology, 2000, 118, A962.	0.6	1
333	Leptin receptor-mediated regulation of cholinergic neurotransmitter phenotype in cells of central nervous system origin. , 2000, 267, 2939.		1
334	Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2615-2620.	3.3	172
335	Presence of a reduced opioid response in interleukin-6 knock out mice. European Journal of Neuroscience, 1999, 11, 1501-1507.	1.2	50
336	Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6417-6422.	3.3	321
337	Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1. Annals of Hematology, 1999, 78, 13-18.	0.8	19
338	Activation of gp130 signaling in vivo by the IL-6 super-agonist K-7 $\alpha$ /D-6 accelerates repopulation of lymphoid organs after irradiation. European Journal of Immunology, 1999, 29, 300-310.	1.6	5
339	Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer, 1999, 85, 134-144.	2.0	75
340	Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity, 1999, 10, 105-115.	6.6	1,512
341	IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. Journal of Leukocyte Biology, 1999, 66, 471-480.	1.5	64
342	Development of Animal Models for Adeno-Associated Virus Site-Specific Integration. Journal of Virology, 1999, 73, 2517-2526.	1.5	46

#	ARTICLE	IF	CITATIONS
343	Role of IL-6 in the pleurisy and lung injury caused by carrageenan. <i>Journal of Immunology</i> , 1999, 163, 5094-104.	0.4	72
344	IL-6 Mediates the Effects of IL-1 or TNF, but Not PTHrP or 1,25(OH)2D3, on Osteoclast-like Cell Formation in Normal Human Bone Marrow Cultures. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 393-399.	3.1	105
345	Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. <i>EMBO Journal</i> , 1998, 17, 5588-5597.	3.5	121
346	In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway. <i>Oncogene</i> , 1998, 17, 1039-1044.	2.6	90
347	IMPAIRED STAT3 ACTIVATION FOLLOWING LOCALIZED INFLAMMATORY STIMULUS IN IL-6-DEFICIENT MICE. <i>Cytokine</i> , 1998, 10, 13-18.	1.4	49
348	Elevation of IL-6 in Transgenic Mice Results in Increased Levels of the 90kDa Heat Shock Protein (hsp90) and the Production of Anti-hsp90 Antibodies. <i>Journal of Autoimmunity</i> , 1998, 11, 249-253.	3.0	26
349	Hepatocellular Hyperplasia, Plasmacytoma Formation, and Extramedullary Hematopoiesis in Interleukin (IL)-6/Soluble IL-6 Receptor Double-Transgenic Mice. <i>American Journal of Pathology</i> , 1998, 153, 639-648.	1.9	86
350	Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina. <i>Circulation</i> , 1998, 98, 2370-2376.	1.6	292
351	Interleukin 6 Is Required for the Development of Collagen-induced Arthritis. <i>Journal of Experimental Medicine</i> , 1998, 187, 461-468.	4.2	545
352	Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. <i>Biochemical Journal</i> , 1998, 331, 695-702.	1.7	77
353	Human Herpesvirus Type 8 Interleukin-6 Homologue Is Functionally Active on Human Myeloma Cells. <i>Blood</i> , 1998, 91, 1858-1863.	0.6	190
354	Site-Specific Integration in Mammalian Cells Mediated by a New Hybrid Baculovirus-Adeno-Associated Virus Vector. <i>Journal of Virology</i> , 1998, 72, 5025-5034.	1.5	95
355	CCAAT enhancer-binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy. <i>Journal of Clinical Investigation</i> , 1998, 102, 996-1007.	3.9	253
356	Human Herpesvirus Type 8 Interleukin-6 Homologue Is Functionally Active on Human Myeloma Cells. <i>Blood</i> , 1998, 91, 1858-1863.	0.6	7
357	Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. <i>Blood</i> , 1998, 91, 1858-63.	0.6	61
358	Extramedullary Expansion of Hematopoietic Progenitor Cells in Interleukin (IL)-6/sIL-6R Double Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1997, 185, 755-766.	4.2	167
359	Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. <i>Immunity</i> , 1997, 6, 315-325.	6.6	1,022
360	The receptor super-antagonist Sant7. <i>Oncology Reports</i> , 1997, 4, 485-92.	1.2	5



#	ARTICLE	IF	CITATIONS
361	Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6456-6461.	3.3	193
362	Adenovirus-mediated gene transfer of a human IL-6 antagonist. Gene Therapy, 1997, 4, 839-845.	2.3	11
363	Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nature Biotechnology, 1997, 15, 997-1001.	9.4	38
364	Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.. Journal of Clinical Investigation, 1997, 99, 643-650.	3.9	449
365	Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. American Journal of Pathology, 1997, 151, 689-96.	1.9	92
366	Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. Journal of Immunology, 1997, 159, 1474-81.	0.4	37
367	Coupling Protein Design and in Vitro Selection Strategies: Improving Specificity and Affinity of a Designed $\hat{I}^2$ -protein IL-6 Antagonist. Journal of Molecular Biology, 1996, 255, 86-97.	2.0	73
368	Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice. Science, 1996, 274, 1379-1383.	6.0	1,441
369	Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.. EMBO Journal, 1996, 15, 2726-2737.	3.5	55
370	Overexpression of interleukin-6 in the central nervous system of transgenic mice increases central but not systemic proinflammatory cytokine production. Brain Research, 1996, 740, 239-244.	1.1	42
371	Functional Expression of Soluble Human Interleukin-11 (IL-11) Receptor $\hat{I}^{\pm}$ and Stoichiometry of in Vitro IL-11 Receptor Complexes with gp130. Journal of Biological Chemistry, 1996, 271, 30986-30991.	1.6	54
372	Elevated Levels of Interleukin-6 in Unstable Angina. Circulation, 1996, 94, 874-877.	1.6	588
373	Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO Journal, 1996, 15, 2726-37.	3.5	4
374	Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Research, 1996, 56, 4213-8.	0.4	51
375	IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. Journal of Immunology, 1996, 157, 2618-23.	0.4	38
376	IL-6 Expression in Neurons of Transgenic Mice Causes Reactive Astrocytosis and Increase in Ramified Microglial Cells but no Neuronal Damage. European Journal of Neuroscience, 1995, 7, 2441-2449.	1.2	153
377	Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.. EMBO Journal, 1995, 14, 1942-1951.	3.5	205
378	Interleukin-6 (IL-6) Antagonism by Soluble IL-6 Receptor $\hat{I}^{\circ}$ Mutated in the Predicted gp130-binding Interface. Journal of Biological Chemistry, 1995, 270, 12242-12249.	1.6	38



#	ARTICLE	IF	CITATIONS
379	Definition of a Composite Binding Site for gp130 in Human Interleukin-6. Journal of Biological Chemistry, 1995, 270, 31249-31254.	1.6	32
380	Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix. Gene, 1995, 167, 41-47.	1.0	34
381	In vitro Binding of Ciliary Neurotrophic Factor to its Receptors: Evidence for the Formation of an IL-6-type Hexameric Complex. Journal of Molecular Biology, 1995, 254, 795-800.	2.0	55
382	The Molecular Design of Human IL-6 Receptor Antagonists. Annals of the New York Academy of Sciences, 1995, 762, 136-151.	1.8	7
383	Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO Journal, 1995, 14, 1942-51.	3.5	49
384	Loss of heterozygosity of imprinted genes in SV40 t/T antigen-induced hepatocellular carcinomas. Oncogene, 1995, 11, 711-21.	2.6	26
385	Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.. EMBO Journal, 1994, 13, 1189-1196.	3.5	653
386	Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.. EMBO Journal, 1994, 13, 1357-1367.	3.5	118
387	The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.. EMBO Journal, 1994, 13, 5303-5309.	3.5	62
388	Rational design of a receptor super-antagonist of human interleukin-6.. EMBO Journal, 1994, 13, 5863-5870.	3.5	123
389	Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood, 1994, 83, 2570-2579.	0.6	121
390	A fast and sensitive colorimetric assay for IL-6 in hepatoma cells based on the production of a secreted form of alkaline phosphatase (SEAP). Journal of Immunological Methods, 1994, 170, 47-56.	0.6	13
391	High Yield Expression and Purification of Human Endothelin-1. Protein Expression and Purification, 1994, 5, 559-568.	0.6	4
392	Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors. Journal of Biological Chemistry, 1994, 269, 10991-10995.	1.6	54
393	Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO Journal, 1994, 13, 1189-96.	3.5	197
394	Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO Journal, 1994, 13, 1357-67.	3.5	33
395	The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. EMBO Journal, 1994, 13, 5303-9.	3.5	14
396	Rational design of a receptor super-antagonist of human interleukin-6. EMBO Journal, 1994, 13, 5863-70.	3.5	23

#	ARTICLE	IF	CITATIONS
397	Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. <i>Blood</i> , 1994, 83, 2570-9.	0.6	37
398	A Multimeric Synthetic Peptide Combinatorial Library. <i>Peptide Research</i> , 1994, 7, 27-31.	0.2	2
399	Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors. <i>Journal of Biological Chemistry</i> , 1994, 269, 10991-5.	1.6	48
400	Involvement of the Arg179 in the active site of human IL-6. <i>FEBS Journal</i> , 1993, 211, 749-755.	0.2	47
401	Structural characterization of a biologically active human lipocortin 1 expressed in <i>Escherichia coli</i> . <i>FEBS Journal</i> , 1993, 211, 347-355.	0.2	20
402	Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1. <i>British Journal of Pharmacology</i> , 1993, 108, 573-574.	2.7	74
403	The two C/EBP isoforms, IL6DBP/NFIL6 and CEBP6/NFIL63, are induced by IL6 to promote acute phase gene transcription via different mechanisms. <i>Nucleic Acids Research</i> , 1993, 21, 289-294.	6.5	171
404	A Bipartite Activation Domain Is Responsible for the Activity of Transcription Factor HNF1/LFB1 in Cells of Hepatic and Nonhepatic Origin. <i>DNA and Cell Biology</i> , 1993, 12, 199-208.	0.9	12
405	Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 4067-4071.	3.3	76
406	Transcriptional Control of Gene Expression in Hepatic Cells. , 1993, , 162-242.		2
407	Inducible formation of liver tumors in transgenic mice. <i>Oncogene</i> , 1993, 8, 87-93.	2.6	19
408	Expression of the murine interleukin 6 receptor in hepatoma cells: the intracytoplasmic domain is not required for interleukin 6 signal transduction. <i>European Journal of Immunology</i> , 1992, 22, 799-804.	1.6	26
409	Analysis of human/mouse interleukin-6 hybrid proteins: both amino and carboxy termini of human interleukin-6 are required for in vitro receptor binding. <i>European Journal of Immunology</i> , 1992, 22, 2609-2615.	1.6	28
410	Constitutive and modulated expression of the human alpha 1 antitrypsin gene. Different transcriptional initiation sites used in three different cell types.. <i>Journal of Clinical Investigation</i> , 1992, 89, 1214-1222.	3.9	56
411	Internal deletions in human interleukin-6: structure-function analysis. <i>Gene</i> , 1991, 104, 227-234.	1.0	16
412	A <i>Zenopus</i> multifinger protein, Xfin, is expressed in specialized cell types and is localized in the cytoplasm. <i>Mechanisms of Development</i> , 1991, 36, 31-40.	1.7	8
413	Internal deletions of amino acids 29-42 of human interleukin-6 (IL-6) differentially affect bioactivity and folding. <i>FEBS Letters</i> , 1991, 288, 197-200.	1.3	18
414	Single-step purification and structural characterization of human interleukin-6 produced in <i>Escherichia coli</i> From a T7 RNA polymerase expression vector. <i>FEBS Journal</i> , 1991, 198, 541-547.	0.2	128

#	ARTICLE	IF	CITATIONS
415	Binding of a liver-specific factor to the human albumin gene promoter and enhancer.. Molecular and Cellular Biology, 1990, 10, 991-999.	1.1	38
416	Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter.. EMBO Journal, 1990, 9, 457-465.	3.5	162
417	Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.. EMBO Journal, 1990, 9, 4467-4475.	3.5	134
418	Liver-specific and inducible expression of oncogenes in transgenic mice. Pharmacological Research, 1990, 22, 112.	3.1	0
419	Binding of a Liver-Specific Factor to the Human Albumin Gene Promoter and Enhancer. Molecular and Cellular Biology, 1990, 10, 991-999.	1.1	11
420	Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter. EMBO Journal, 1990, 9, 457-65.	3.5	67
421	Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO Journal, 1990, 9, 4467-75.	3.5	64
422	Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer. Molecular Biology & Medicine, 1990, 7, 199-212.	1.7	25
423	Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6.. EMBO Journal, 1989, 8, 3773-3779.	3.5	239
424	Characterization of mononuclear-phagocyte terminal maturation by mRNA phenotyping using a set of cloned cDNA probes. FEBS Journal, 1989, 185, 291-296.	0.2	12
425	Transcriptional Regulation of Acute Phase Response Genes with Emphasis on the Human C-reactive Protein Gene. The Argenteuil Symposia, 1989, , 29-46.	0.1	11
426	Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO Journal, 1989, 8, 3773-9.	3.5	92
427	Identification of sequences responsible for acute-phase induction of human C-reactive protein. Nucleic Acids Research, 1988, 16, 3195-3207.	6.5	93
428	Structure and expression of a Xenopus gene encoding an snRNP protein (U1 70K).. EMBO Journal, 1988, 7, 4311-4321.	3.5	58
429	Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes.. Journal of Biological Chemistry, 1988, 263, 12554-12558.	1.6	193
430	Structure and expression of a Xenopus gene encoding an snRNP protein (U1 70K). EMBO Journal, 1988, 7, 4311-21.	3.5	34
431	Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. Journal of Biological Chemistry, 1988, 263, 12554-8.	1.6	164
432	Properties of a U1 RNA enhancer-like sequence. Nucleic Acids Research, 1987, 15, 2403-2416.	6.5	50

#	ARTICLE	IF	CITATIONS
433	DNA sequence of a pseudogene for human C-reactive protein. <i>Nucleic Acids Research</i> , 1987, 15, 5895-5895.	6.5	6
434	The human alpha 1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes.. <i>EMBO Journal</i> , 1987, 6, 2767-2771.	3.5	169
435	Cis- and trans-acting elements responsible for the cell-specific expression of the human alpha 1-antitrypsin gene.. <i>EMBO Journal</i> , 1987, 6, 2759-2766.	3.5	159
436	Inducible and tissue-specific expression of human C-reactive protein in transgenic mice.. <i>EMBO Journal</i> , 1987, 6, 4017-4022.	3.5	119
437	Cis- and trans-acting elements responsible for the cell-specific expression of the human alpha 1-antitrypsin gene. <i>EMBO Journal</i> , 1987, 6, 2759-66.	3.5	85
438	The human alpha 1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. <i>EMBO Journal</i> , 1987, 6, 2767-71.	3.5	70
439	Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. <i>EMBO Journal</i> , 1987, 6, 4017-22.	3.5	47
440	Formation of the 3' end on U snRNAs requires at least three sequence elements.. <i>EMBO Journal</i> , 1986, 5, 2931-2937.	3.5	56
441	Formation of the 3' end on U snRNAs requires at least three sequence elements. <i>EMBO Journal</i> , 1986, 5, 2931-7.	3.5	40
442	Transcription signals in embryonic <i>Xenopus laevis</i> U1 RNA genes.. <i>EMBO Journal</i> , 1985, 4, 1537-1543.	3.5	89
443	Functional activity and chromatin configuration of SV40 enhancer injected in <i>Xenopus laevis</i> oocytes. <i>Nucleic Acids Research</i> , 1985, 13, 8065-8081.	6.5	15
444	Alu sequences transcription in <i>X. laevis</i> oocytes: nuclear-cytoplasmic partitioning and evidence for 3' end processing reactions. <i>Nucleic Acids Research</i> , 1985, 13, 8359-8377.	6.5	31
445	Structure of the human $\alpha$ 1-acid glycoprotein gene: sequence homology with other human acute phase protein genes. <i>Nucleic Acids Research</i> , 1985, 13, 3941-3952.	6.5	123
446	Cell-specific expression of a transfected human $\alpha$ 1-antitrypsin gene. <i>Cell</i> , 1985, 41, 531-540.	13.5	202
447	Transcription signals in embryonic <i>Xenopus laevis</i> U1 RNA genes. <i>EMBO Journal</i> , 1985, 4, 1537-43.	3.5	53
448	Inhibition of eukaryotic tRNA transcription by potential Z-DNA sequences.. <i>EMBO Journal</i> , 1984, 3, 1553-1559.	3.5	40
449	Transcription of multimeric tRNA genes. <i>Nucleic Acids Research</i> , 1984, 12, 1277-1285.	6.5	3
450	Mutations in box B of the promoter of a eucaryotic tRNA <sup>Pro</sup> gene affect rate of transcription, processing, and stability of the transcripts. <i>Cell</i> , 1984, 36, 179-187.	13.5	58

#	ARTICLE	IF	CITATIONS
451	Inhibition of eukaryotic tRNA transcription by potential Z-DNA sequences. <i>EMBO Journal</i> , 1984, 3, 1553-9.	3.5	16
452	Isolation and characterization of a tRNA(guanine-7)-methyltransferase from <i>Salmonella typhimurium</i> . <i>Molecular and Cellular Biochemistry</i> , 1983, 52, 97-106.	1.4	5
453	Common and interchangeable elements in the promoters of genes transcribed by RNA polymerase III. <i>Cell</i> , 1983, 32, 725-733.	13.5	186
454	A general method to select for M13 clones carrying base pair substitution mutants constructed <i>in vitro</i> . <i>Nucleic Acids Research</i> , 1983, 11, 4229-4239.	6.5	25
455	Chapter 3 Transcription By RNA Polymerase III. <i>Current Topics in Developmental Biology</i> , 1983, 18, 59-88.	1.0	155
456	Functional assay of tRNA molecules transcribed from a purified gene. <i>Nucleic Acids Research</i> , 1982, 10, 7363-7372.	6.5	4
457	Processing of eukaryotic tRNA precursors: secondary structure of the precursor specific sequences affects the rate but not the accuracy of processing reactions. <i>Nucleic Acids Research</i> , 1982, 10, 4135-4145.	6.5	23
458	Promoter of a eukaryotic tRNA <sup>Pro</sup> gene is composed of three noncontiguous regions.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982, 79, 1195-1199.	3.3	140
459	Relationship between the two components of the split promoter of eukaryotic tRNA genes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982, 79, 1921-1925.	3.3	84
460	Effect of adenosylhomocysteine and other analog thioethers on a prokaryotic tRNA (guanine-7)-methyltransferase. <i>Archives of Biochemistry and Biophysics</i> , 1982, 219, 149-154.	1.4	5
461	A prokaryotic tRNA <sup>Tyr</sup> gene, inactive in <i>Xenopus laevis</i> oocytes, is activated by recombination with an eukaryotic tRNA <sup>Pro</sup> gene.. <i>EMBO Journal</i> , 1982, 1, 817-820.	3.5	5
462	A novel method for site-directed mutagenesis: its application to an eukaryotic tRNA <sup>Pro</sup> gene promoter.. <i>EMBO Journal</i> , 1982, 1, 415-420.	3.5	71
463	A novel method for site-directed mutagenesis: its application to an eukaryotic tRNA <sup>Pro</sup> gene promoter. <i>EMBO Journal</i> , 1982, 1, 415-20.	3.5	40
464	A prokaryotic tRNA <sup>Tyr</sup> gene, inactive in <i>Xenopus laevis</i> oocytes, is activated by recombination with an eukaryotic tRNA <sup>Pro</sup> gene. <i>EMBO Journal</i> , 1982, 1, 817-20.	3.5	2
465	Purification of pseudouridylate synthetase I from <i>Salmonella typhimurium</i> . <i>Nucleic Acids Research</i> , 1978, 5, 4523-4536.	6.5	37
466	Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines. , 0, , .		4
467	Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2